Consilium Wealth Advisory LLC Trims Stock Holdings in Eli Lilly and Company $LLY

Consilium Wealth Advisory LLC lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 9.1% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 3,032 shares of the company’s stock after selling 305 shares during the period. Eli Lilly and Company comprises about 1.0% of Consilium Wealth Advisory LLC’s portfolio, making the stock its 24th largest holding. Consilium Wealth Advisory LLC’s holdings in Eli Lilly and Company were worth $2,363,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Family CFO Inc acquired a new position in shares of Eli Lilly and Company during the 2nd quarter worth approximately $54,000. Duquesne Family Office LLC lifted its holdings in Eli Lilly and Company by 52.5% in the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock valued at $78,321,000 after acquiring an additional 32,640 shares during the last quarter. Corient IA LLC acquired a new position in Eli Lilly and Company in the first quarter valued at approximately $570,000. Cutter Capital Management LP acquired a new position in Eli Lilly and Company in the first quarter valued at approximately $14,866,000. Finally, Emerald Advisors LLC lifted its holdings in Eli Lilly and Company by 60.8% in the second quarter. Emerald Advisors LLC now owns 1,021 shares of the company’s stock valued at $796,000 after acquiring an additional 386 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Morgan Stanley decreased their price objective on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a report on Friday. JPMorgan Chase & Co. cut their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research report on Tuesday, September 16th. Leerink Partnrs lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. HSBC raised Eli Lilly and Company from a “reduce” rating to a “hold” rating and boosted their target price for the company from $675.00 to $700.00 in a research report on Wednesday, August 27th. Finally, Daiwa Capital Markets lowered Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price on the stock. in a research report on Sunday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $933.39.

Eli Lilly and Company Stock Up 2.5%

Eli Lilly and Company stock opened at $840.46 on Friday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $937.00. The stock’s fifty day simple moving average is $734.60 and its 200-day simple moving average is $766.47. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The firm has a market capitalization of $795.47 billion, a P/E ratio of 54.93, a P/E/G ratio of 1.14 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the prior year, the company earned $3.92 earnings per share. The company’s revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Buying and Selling at Eli Lilly and Company

In related news, Director J Erik Fyrwald acquired 1,565 shares of the business’s stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the transaction, the director owned 74,578 shares of the company’s stock, valued at $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Daniel Skovronsky acquired 1,000 shares of the business’s stock in a transaction dated Tuesday, August 12th. The shares were bought at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the transaction, the executive vice president directly owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. This trade represents a 0.73% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 4,514 shares of company stock valued at $2,894,841. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.